Market Overview

UBS Analysts Might've Found Another BioMarin Catalyst

UBS Analysts Might've Found Another BioMarin Catalyst
Related BMRN
The Week Ahead In Biotech: PDUFA Dates, IPOs And More
Why Leerink Adjusted Upside Expectations For 3 Biotechs

In a report published Friday, UBS analyst Andrew Peters maintained a Buy rating on BioMarin Pharmaceutical Inc (NASDAQ: BMRN), with a price target of $155, after survey data revealed high optionality on BMN270.

Peters said that an analysis of the trends in the Hemophilia market revealed that both patients and caregivers appeared excited about new technologies that offered better safety and improved dosage, along with features like bleed control.

The survey data suggested that nearly half of the patients would be willing to adopt a gene therapy product within two years after its launch, Peters added.

Although no clinical data for BMN270 was available so far, pre-clinical data showed restoration of Factor VIII in plasma sufficient to support normal clotting levels in humans. The UBS report added that the technology was licensed from University College in London, which had published "encouraging clinical data in Hern B."

BioMarin Pharmaceutical was expected to provide initial data on BMN270 in 1H16 and Peters expects "meaningful upside" in the event of a "positive read out."

Latest Ratings for BMRN

Mar 2018Credit SuisseMaintainsOutperformOutperform
Feb 2018Morgan StanleyMaintainsOverweightOverweight
Feb 2018Stifel NicolausMaintainsBuyBuy

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Previews Reiteration Analyst Ratings Trading Ideas General Best of Benzinga


Related Articles (BMRN)

View Comments and Join the Discussion!